Biotech News

Belite Bio Announces Uplisting to the Nasdaq Global Select Market

Belite Bio (BLTE)Belite Bio2026-10-19 10:00 ESTFDA / regulatory

Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio ® ” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has received approval from Nasdaq to transfer the listing of its securities from the Nasdaq Capital Market to the Nasdaq Global Select Market. Trading on the Nasdaq Global Select Market will commence at the open of market on October 19, 2026, under the Company’s existing ticker symbol “BLTE.”

Related news

BLTEBelite Bio2026-10-14 20:00 EST

Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1

RHHBYRoche Holdings AG2026-10-16 05:00 EST

FDA approves Roche’s Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)

OTLKOutlook2026-10-06 13:20 EST

Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion

BLTEBelite Bio2026-09-29 00:00 EST

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

OCGNOcugen2026-09-25 11:02 EST

Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa

OTLKOutlook2026-09-10 13:10 EST

Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment

RHHBYRoche Holdings AG2026-10-09 05:00 EST

FDA approves Roche’s Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer

NAMSNewAmsterdam Pharma2026-09-21 13:00 EST

NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)

MISTMilestone Pharmaceuticals Inc.2026-09-03 13:35 EST

Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States

TARSTarsus Pharmaceuticals2026-08-06 11:01 EST

Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position

View all latest news

Belite Bio

Retinal Degeneration Company Belite Bio develops therapies for Stargardt disease type 1, geographic atrophy secondary to advanced dry age-related macular degeneration, and selected metabolic disorders. Lead candidate tinlarebant is an oral therapy designed to reduce the accumulation of bisretinoid toxins in the eye. Tinlarebant...

Recent company news

BLTEBelite Bio2026-10-19 10:00 EST

Belite Bio Announces Uplisting to the Nasdaq Global Select Market

BLTEBelite Bio2026-10-14 20:00 EST

Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1

BLTEBelite Bio2026-09-29 00:00 EST

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

BLTEBelite Bio2026-09-08 10:00 EST

Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1

BLTEBelite Bio2026-09-01 12:00 EST

Belite Bio to Participate in Four Upcoming Investor Conferences

Stock data

Close: 153.18 USD
Market cap: 5.41B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States